Price Alert

Zymeworks Inc. (ZYME)

NASDAQ: ZYME · Real-Time Price · USD

14.08

-0.06 (-0.42%)

At close: Sep 04, 2025, 3:59 PM

14.25

1.21%

After-hours: Sep 04, 2025, 04:12 PM EDT

-0.42% (1D)

Bid	13.52
Market Cap	1.06B
Revenue (ttm)	122.87M
Net Income (ttm)	-73.67M
EPS (ttm)	-0.98
PE Ratio (ttm)	-14.37
Forward PE	-13.6
Analyst	Buy

Ask	14.5
Volume	422,278
Avg. Volume (20D)	471,103
Open	14.14
Previous Close	14.14
Day's Range	14.05 - 14.47
52-Week Range	9.03 - 17.70
Beta	1.26

About ZYME

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ZYME

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ZYME stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Zymeworks Inc. is scheduled to release its earnings on Oct 30, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 days ago

-5.4%

Zymeworks shares are trading lower after the compa... Unlock content with Pro Subscription

6 months ago

-7.97%

Zymeworks shares are trading lower after the company reported worse-than-expected Q4 financial results.

News

2 days ago · seekingalpha.com

Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On

I maintain my Strong Buy rating on Zymeworks Inc., driven by its robust ADC pipeline and upcoming pivotal zanidatamab data in late 2025. ZW171 was discontinued due to on-target off-tumor toxicity, but...

1 day ago · benzinga.com

Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit

Zymeworks Inc. ZYME on Tuesday decided to voluntarily discontinue clinical development of ZW171, a T-cell engager designed to target gynecological, thoracic, and digestive system cancers.

2 days ago · reuters.com

Zymeworks halts development of cancer drug after trial setback

Zymeworks said on Tuesday it will stop developing its experimental cancer drug after results from a trial showed the treatment was unlikely to meet the company's goals as a standalone therapy.

3 weeks ago · zacks.com

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zymeworks (ZYME) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a t...

3 weeks ago · seekingalpha.com

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

Zymeworks Inc. (NASDAQ:ZYME ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Kenneth H. Galbraith - Chairman of the Board, CEO & President Leone D.

4 weeks ago · zacks.com

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

Zymeworks Inc. (ZYME) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.52 per share. This compares to a loss of $0.26 per share a year ago.

1 month ago · zacks.com

Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?

Zymeworks (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r...

2 months ago · zacks.com

All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy

Zymeworks (ZYME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · seekingalpha.com

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

Zymeworks Inc.'s lead asset zanidatamab won FDA approval for HER2-positive biliary tract cancer, validating its platform but addressing a small market. The main investment thesis hinges on upcoming Ph...

3 months ago · zacks.com

Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?

The consensus price target hints at a 76.7% upside potential for Zymeworks (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat...